IN2012DN05888A - - Google Patents

Info

Publication number
IN2012DN05888A
IN2012DN05888A IN5888DEN2012A IN2012DN05888A IN 2012DN05888 A IN2012DN05888 A IN 2012DN05888A IN 5888DEN2012 A IN5888DEN2012 A IN 5888DEN2012A IN 2012DN05888 A IN2012DN05888 A IN 2012DN05888A
Authority
IN
India
Prior art keywords
pro
emulsion formulations
taxane
kits
making
Prior art date
Application number
Other languages
English (en)
Inventor
Kiichiro Nabeta
Original Assignee
Teikoku Pharma Usa Inc
Techno Guard Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma Usa Inc, Techno Guard Co Ltd filed Critical Teikoku Pharma Usa Inc
Publication of IN2012DN05888A publication Critical patent/IN2012DN05888A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN5888DEN2012 2010-02-19 2011-02-18 IN2012DN05888A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30631510P 2010-02-19 2010-02-19
PCT/US2011/025418 WO2011103413A2 (fr) 2010-02-19 2011-02-18 Formulations de pro-émulsion de taxane et leurs procédés de fabrication et d'utilisation

Publications (1)

Publication Number Publication Date
IN2012DN05888A true IN2012DN05888A (fr) 2015-09-18

Family

ID=44477026

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5888DEN2012 IN2012DN05888A (fr) 2010-02-19 2011-02-18

Country Status (9)

Country Link
US (2) US8569357B2 (fr)
EP (1) EP2536407A4 (fr)
JP (1) JP2013520435A (fr)
KR (1) KR20120126072A (fr)
CN (1) CN102762202A (fr)
AU (1) AU2011217951B2 (fr)
IN (1) IN2012DN05888A (fr)
TW (1) TWI438009B (fr)
WO (1) WO2011103413A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013268725B2 (en) * 2012-05-31 2017-02-16 Asahi Kasei Pharma Corporation Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5698582A (en) * 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5750561A (en) * 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
DE4208527A1 (de) * 1992-03-17 1993-09-23 Max Planck Gesellschaft Liposomen mit negativer ueberschussladung
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
JP2880292B2 (ja) * 1992-11-27 1999-04-05 ナプロ バイオセラピューティクス，インコーポレイテッド 注射可能組成物
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
WO1994018954A1 (fr) * 1993-02-22 1994-09-01 Vivorx Pharmaceuticals, Inc. Procedes d'administration in vivo de substances biologiques et compositions utilisees dans ces procedes
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
DE4447770C2 (de) * 1994-08-20 2002-12-19 Max Delbrueck Centrum Verfahren zur Herstellung von liposomal verkapseltem Taxol
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP0760237A1 (fr) * 1995-08-30 1997-03-05 Cipla Limited Microémulsions huile-dans-l'eau
KR100330373B1 (ko) * 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6121245A (en) * 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
BR9810866B1 (pt) * 1997-07-29 2010-07-13 composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos.
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6281175B1 (en) * 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
AU2845599A (en) * 1998-03-05 1999-09-20 Phares Pharmaceutical Research N.V. Pharmaceutical compositions and their use
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
TR200003435T2 (tr) * 1998-05-20 2001-03-21 The Liposome Company,Inc. Yeni parçacıklı formülasyonlar
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
CA2373994A1 (fr) * 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Excipient en emulsion pour medicaments faiblement solubles
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
CN100376291C (zh) * 1999-05-27 2008-03-26 阿库斯菲尔公司 多孔药物基质及其制造方法
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
TW422706B (en) * 1999-07-01 2001-02-21 Wang Iz Rung An oil-in-water emulsion type of paclitaxel
US6348215B1 (en) * 1999-10-06 2002-02-19 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6638973B2 (en) * 2000-02-02 2003-10-28 Fsu Research Foundation, Inc. Taxane formulations
JP3448006B2 (ja) * 2000-03-29 2003-09-16 独立行政法人食品総合研究所 機能性エマルション
US6761901B1 (en) * 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US20030099674A1 (en) * 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
US20060078618A1 (en) * 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
WO2004018312A1 (fr) * 2002-08-21 2004-03-04 Pharmacia Corporation Suspension pharmaceutique injectable dans une fiole a deux chambres
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
WO2008105852A2 (fr) * 2006-10-26 2008-09-04 Creighton University Nanoparticules mucoadhésives pour traitement anticancéreux
WO2010018596A2 (fr) * 2008-07-23 2010-02-18 Bharat Serums And Vaccines Ltd. Nanoémulsion huile dans l'eau injectable stable de docétaxel
CN101428002A (zh) * 2008-11-20 2009-05-13 沈阳万爱普利德医药科技有限公司 注射用紫杉醇冻干微乳剂及其制备方法

Also Published As

Publication number Publication date
EP2536407A4 (fr) 2013-08-14
EP2536407A2 (fr) 2012-12-26
US20110207803A1 (en) 2011-08-25
WO2011103413A3 (fr) 2012-01-12
WO2011103413A2 (fr) 2011-08-25
KR20120126072A (ko) 2012-11-20
US20140088181A1 (en) 2014-03-27
TW201141538A (en) 2011-12-01
US8569357B2 (en) 2013-10-29
CN102762202A (zh) 2012-10-31
JP2013520435A (ja) 2013-06-06
TWI438009B (zh) 2014-05-21
AU2011217951A1 (en) 2012-07-19
AU2011217951B2 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
WO2013177419A3 (fr) Compositions de nanoparticules lipidiques ainsi que procédés de fabrication et procédés d'utilisation de celles-ci
WO2012077120A3 (fr) Formulations naturelles
WO2013123114A3 (fr) Formulations d'anticorps
WO2012051210A3 (fr) Cellules souches mésenchymateuses et thérapies connexes
GEP201706733B (en) Anti-il-23 antibodies
WO2012099930A3 (fr) Compositions de flavonol
WO2011133504A3 (fr) Nanozymes, procédés de production de nanozymes, et procédés d'utilisation de nanozymes
MY170720A (en) Antibody formulations
ZA201401782B (en) Chromobacterium formulations,compositions,metabolites and their uses
EP3074000A4 (fr) Compositions de composés phénoliques physiologiquement actifs en suspension& procédés de production utilisant ces compositions
EP3068500A4 (fr) Compositions d'engrais et procédés de fabrication et d'utilisation de celles-ci
PH12012502163A1 (en) Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
IN2012DN03404A (fr)
WO2012075117A3 (fr) Conjugués de petite molécule-polymère et procédés pour leur préparation
WO2013123046A3 (fr) Matériaux tampons de cathode et dispositifs et procédés associés
CA2875305C (fr) Inhibiteurs de fbxo-3
WO2012088222A3 (fr) Procédés et compositions pour la production de protéines actives dépendantes de la vitamine k
WO2011050188A8 (fr) Anticorps anti-hepsine et procédés d'utilisation de ceux-ci
EP2640953A4 (fr) Compositions de propergol et procédés de fabrication et d'utilisation de ces compositions
IN2012DN05888A (fr)
MX2013000539A (es) Nuevas formulaciones de analogos 14-epi de la vitamina d.
WO2012051126A3 (fr) Macrolides antiinflammatoires
WO2014003950A3 (fr) Nucléosides contenant du sélénium en tant que suppléments nutritionnels
WO2012139074A3 (fr) Migrastatines et leurs utilisations
WO2012004073A3 (fr) UTILISATION DE β-ISOPHORONE COMME SOLVANT